Nov 29, 2018
John J. O’Shea, MD, is scientific director of the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases, and chief of their Molecular Immunology and Inflammation Branch. In this ACR interview, he joins me to talk about the JAK/STAT pathway, what we’ve learned from mouse models, current FDA-approved JAK inhibitors and the future of this exciting field.
- Intro :10
- Background on Dr. O’Shea :45
- The interview 2:37
- How did you start looking into the JAK/STAT pathway? 3:16
- What should a clinician understand about this pathway? 5:22
- What do these cytokines have in common? 6:37
- What have we learned from mouse models? 8:48
- GWAS studies in JAK/STAT 11:49
- Can we quantify how much a certain cytokine may be using this pathway? 12:39
- Can you explain suppressor of cytokine signaling, aka SOCS? 14:15
- What do we know about how these different cytokines can have
individual signaling controls? 16:40
- An explanation of phenocopy 18:01
- What evidence do we have that JAK may circumvent STAT, and vice versa? 18:41
- An overview of FDA-approved JAK inhibitors and the pipeline 20:52
- What excites you the most about the future of this field? 23:26
- In a state of wonder over success of biologics 25:50
- Thank you, Dr. O’Shea 27:20
- Recap 27:30
We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. And be sure to follow us on Twitter @AdamJBrownMD and @HealioRheum.
This information is brought to you by Healio and is not sponsored by, nor a part of, the American College of Rheumatology.